Heptatriacontan-19-yl methanesulfonate | 952056-48-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机磺酸及其衍生物
• 英文名称: Heptatriacontan-19-yl methanesulfonate
• CAS: 952056-48-3
• 化学式: C₃₈H₇₈O₃S
• 分子量: 615.102
• InChiKey: OFALNWDFQJABFJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  18.5
• 重原子数：
  42
• 可旋转键数：
  36
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  51.8
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  Heptatriacontan-19-yl methanesulfonate 在 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 反应 44.0h， 生成 2-Octadecylicosan-1-amine
  参考文献：
  名称：

  [EN] DI-ALIPHATIC SUBSTITUTED PEGYLATED LIPIDS
  [FR] LIPIDES DI-ALIPHATIQUES PEGYLÉS SUBSTITUÉS

  摘要：

  公开号：

  WO2013049328A9
• 作为产物：
  描述：

  heptatriacontan-19-ol 、 甲基磺酰氯 在 4-二甲氨基吡啶 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 0.5h， 以95.5%的产率得到Heptatriacontan-19-yl methanesulfonate
  参考文献：
  名称：

  Di-aliphatic substituted pegylated lipids

  摘要：

  该公开涉及二烷基取代的PEG化脂质及其制备方法。该公开还涉及含有二烷基取代的PEG化脂质的脂质共轭物，以及在药物传递中使用二烷基取代的PEG化脂质共轭物。

  公开号：

  US09701623B2

文献信息

• Compositions for transfection of oligonucleotides active for gene silencing and their biological and therapeutical applications
  申请人：Polyplus-Transfection SA

  公开号：EP1844772A1

  公开（公告）日：2007-10-17

  The invention relates the compositions of transfection comprising an oligonucleotide active for RNA interference and an amphiphilic cationic molecule of formula (I) wherein - X is N-R1, S or 0, R1 being a C1-C4 alkyl radical or an hydroxylated C3- C6 alkyl radical, - R2 and R3, identical or different, represent H or a C1-C4 alkyl radical, or R2 and R3 are linked together to form a cycle or a heterocycle having 6 elements, - E is a C1-C5 alkyl spacer, - R4 and R5, identical or different, represent saturated or unsaturated, linear or branched, C10-C36 hydrocarbon or fluorocarbon chains, optionally comprising C3-C6 cycloalkyle, - A- is a biocompatible anion. Use of said compositions as drugs.

  该发明涉及包含用于RNA干扰的寡核苷酸活性和具有以下结构的两性阳离子分子的转染组合物：其中- X为N-R1、S或O，其中R1是C1-C4烷基基团或羟基化的C3-C6烷基基团，- R2和R3，相同或不同，代表H或C1-C4烷基基团，或者R2和R3连接在一起形成具有6个元素的环或杂环，- E是C1-C5烷基间隔，- R4和R5，相同或不同，代表饱和或不饱和的线性或支链的C10-C36烃基或氟烃基链，可选地包括C3-C6环烷基，- A-是生物相容性阴离子。将该组合物用作药物。
• COMPOSITIONS FOR TRANSFECTION OF OLIGONUCLEOTIDES ACTIVE FOR GENE SILENCING AND THEIR BIOLOGICAL AND THERAPEUTICAL APPLICATIONS
  申请人：Neuberg Patrick

  公开号：US20100048672A1

  公开（公告）日：2010-02-25

  The invention relates to compositions of transfection comprising an oligonucleotide and an amphiphilic cationic molecule of formula (I) wherein, —X is N—R 1 , S or O, R 1 being a C1-C4 alkyl radical or an hydroxylated C3-C6 alkyl radical, R 2 and R 3 , identical or different, represent H or a C1-C4 alkyl radical, or R 2 and R 3 are linked together to form a saturated or unsaturated cycle or a heterocycle having 5 or 6 elements, E is a C1-C5 alkyl spacer, R 4 and R 5 , identical or different, represent saturated or unsaturated, linear or branched, C10-C36 hydrocarbon or fluorocarbon chains, optionally comprising C3-C6 cycloalkyl, A- is a biocompatible anion. The invention relates to compositions active for oligonucleotides delivery into eukaryotic cells in culture, ex vivo or in vivo. The invention relates to compositions of transfection comprising an oligonucleotide active for RNA interference. Such compositions can be used as tools for biological studies or as drugs for therapies.
• US8399422B2
  申请人：——

  公开号：US8399422B2

  公开（公告）日：2013-03-19
• [EN] DI-ALIPHATIC SUBSTITUTED PEGYLATED LIPIDS<br/>[FR] LIPIDES DI-ALIPHATIQUES PEGYLÉS SUBSTITUÉS
  申请人：ALNYLAM PHARMACEUTICALS INC

  公开号：WO2013049328A9

  公开（公告）日：2013-12-27
• Di-aliphatic substituted pegylated lipids
  申请人：ALNYLAM PHARMACEUTICALS, INC.

  公开号：US09701623B2

  公开（公告）日：2017-07-11

  The disclosure relates to di-aliphatic substituted PEGylated lipids and to methods of their preparation. The disclosure also relates to lipid conjugates containing di-aliphatic substituted PEGylated lipids, and to the use of di-aliphatic substituted PEGylated-lipid conjugates in drug delivery.

  该公开涉及二烷基取代的PEG化脂质及其制备方法。该公开还涉及含有二烷基取代的PEG化脂质的脂质共轭物，以及在药物传递中使用二烷基取代的PEG化脂质共轭物。